Litigation in Nexium, Prilosec Kidney Failure Cases Moving Forward Amid Pandemic Interruptions

The U.S. District Judge presiding over all federal Nexium lawsuitsPrilosec lawsuits and other complaints involving kidney problems linked to proton pump inhibitor (PPI) heartburn drugs is pushing the litigation forward, despite limitations caused by the ongoing COVID-19 global pandemic, with a series of status conferences to be held via telephone and witness depositions continuing remotely.

Makers of the popular heartburn drugs face nearly 14,000 product liability lawsuits brought by individuals throughout the federal court system, each raising similar allegations that users and the medical community were not adequately warned that side effects of proton pump inhibitors may increase the risk of chronic kidney disease, acute kidney injury, kidney failure and other side effects.

Given common questions of fact and law raised in the complaints, coordinated pretrial proceedings have been established before U.S. District Judge Claire C. Cecchi in the U.S. District Court for the District of New Jersey, as part of a federal multidistrict litigation (MDL). The claims are centralized to reduce duplicative discovery into common issues in the cases, avoid conflicting pretrial rulings and serve the convenience of common witnesses, parties and the judicial system.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Prior to the COVID-19 pandemic, the parties were preparing a small group of representative claims for early trial dates, which were expected to begin in November 2021.

While the outcomes of these cases would not binding on other claims, the “bellwether” trials are intended to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout thousands of claims in the litigation, and facilitate eventual Nexium and Prilosec settlement negotiations that may avoid the need for each case to go to trial.

In a case management order (PDF) issued on May 11, Judge Cecchi called for parties to meet and confer on a wide variety of issues in the coming weeks via remote communications methods. The Court indicated it will not require witnesses directly impacted by COVID-19 to sit for their depositions, but others can proceed on a remote basis.

In a letter to the court (PDF), plaintiffs’ attorneys indicated both sides are narrowing their differences on how the remote depositions should be conducted. However, they have come to a crossroads over witness exhibits, with Defendants asking for paper copies despite the ease at which electronic copies could be distributed.

“Defendants seek to take advantage of present conditions by demanding that witnesses and their counsel be provided with hard-copy copies of all exhibits greater than 25 pages, in advance of the deposition,” they wrote. “This is not only unnecessary but inconsistent with the Federal Rules, the parties’ prior practice during depositions, and the very concept of conducting depositions remotely.”

The letter indicates the defendants’ request creates safety risks for attorneys, staff, witnesses, and even those who have to deliver the documents physically, due to the ongoing pandemic.

A letter from defense attorneys (PDF) representing the drug manufacturers claims it is too cumbersome for them to review electronic copies of lengthy and complex documents.

Judge Cecchi has scheduled a telephone case management conference for May 20, where the issue will be discussed. It remains unclear whether delays and disruptions caused by the coronavirus pandemic may require postponement of the November 2021 trial dates.

Nexium, Prilosec Kidney Problems

The proton pump inhibitor litigation first emerged several years ago, following the publication of studies that suggested users may face certain kidney risks that were not disclosed on the warning labels for popular heartburn drugs, including Nexium, Prilosec, Protonix, Prevacid and other medications.

The FDA required new warnings about potential kidney risks for the first time in December 2014, indicating that use of the drugs may increase the risk of a form of kidney damage known as acute interstitial nephritis (AIN), which involves a sudden inflammation of the kidneys, which can lead to more severe problems. However, plaintiffs maintain this warning remains inadequate and vague, failing to mention the drugs may cause an acute kidney injury, chronic kidney disease or kidney failure.

In January 2016, an independent study published in the medical journal JAMA Internal Medicine found an increased risk of chronic kidney disease with the heartburn medications, indicating users of Nexium, Prilosec and other PPI may be 50% more likely when compared to non-users.

These findings were followed by another study published in April 2016, in which researchers with the Department of Veterans Affairs found that users of Nexium, Prilosec or other PPIs may be 96% more likely to develop kidney failure and 28% more likely to develop chronic kidney disease after five years of use.

As consumers have learned about a link between their heartburn drug and kidney problems suffered in recent years, a rapidly growing number of lawsuits have been filed throughout the federal court system.

Following coordinated discovery and a series of bellwether trials, if the parties fail to settle or resolve large numbers of cases, Judge Cecchi may ultimately remand thousands of individual claims back to U.S. District Courts nationwide for individual trial dates in the coming years.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.